Hypersensitivity to stavudine or any of the components contained in the formulation.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. Fatal and nonfatal pancreatitis has been reported during therapy in combination with didanosine.
Zidovudine may competitively inhibit the intracellular phosphorylation of stavudine. Therefore, Stavudine should not be used in combination with zidovudine. Hydroxyurea may enhance the antiretroviral activity of didanosine or stavudine. The addition of hydroxyurea to combination HIV treatment regimens containing didanosine and stavudine has been associated with an increased risk of pancreatitis and hepatotoxocity.
Peripheral neuropathy, headache, anorexia, diarrhea, nausea/vomiting, arthralgia, hypersensitivity, myalgia, pancreatitis.
The clearance of stavudine may be altered in children with renal impairment. Although there are insufficient data to recommend a specific dose adjustment of stavudine in children, a reduction in the dose and/or an increase in the interval between doses should be considered.
The recommended dose is 15 mg orally every 24 hours in patients weighing < 60 kg, administered after the completion of hemodialysis and at the same time of day on non-dialysis days.